Opioids are the gold standard for pharmacological treatment of neuropathic pain, but their analgesic effects are unsatisfactory in part due to nerve injury-induced downregulation of opioid receptors in dorsal root ganglia (DRG) neurons. How nerve injury drives such downregulation remains elusive. DNA methyltransferase (DNMT)-triggered DNA methylation represses gene expression. We show here that blocking the nerve injury-induced increase in DRG DNMT3a (a de novo DNMT) rescued the expression of Oprm1 and Oprk1 mRNAs and their respective encoding mu-opioid receptor (MOR) and kappa-opioid receptor (KOR) proteins in the injured DRG. Blocking this increase also prevented the nerve injury-induced increase in DNA methylation in the promoter and 59-untranslated region of the Oprm1 gene in the injured DRG, restored morphine or loperamide (a peripheral acting MOR preferring agonist) analgesic effects, and attenuated the development of their analgesic tolerance under neuropathic pain conditions. Mimicking this increase reduced the expression of Oprm1 and Oprk1 mRNAs and their coding MOR and KOR in DRG and augmented MOR-gated neurotransmitter release from the primary afferents. Mechanistically, DNMT3a regulation of Oprm1 gene expression required the methyl-CpG-binding protein 1, MBD1, as MBD1 knockout resulted in the decreased binding of DNMT3a to the Oprm1 gene promoter and blocked the DNMT3a-triggered repression of Oprm1 gene expression in DRG neurons. These data suggest that DNMT3a is required for nerve injury-induced and MBD1-mediated epigenetic silencing of the MOR and KOR in the injured DRG. DNMT3a inhibition may serve as a promising adjuvant therapy for opioid use in neuropathic pain management.
Introduction
Nerve injury-induced neuropathic pain is a distressing and debilitating condition affecting approximately 7% of the world population. 41 Health care expenses and lost productivities account for over 100 billion dollars in spending each year. Although recent advances have been made in the therapeutic management of neuropathic pain, opioids, like morphine, remain the mainstay of prescribed medications in the treatment of this disorder. However, approximately two-thirds of patients show unsatisfactory pain control. 27 Moreover, a majority of patients with neuropathic pain require higher doses of opioids as well as repeated and prolonged administration of opioids to achieve pain relief. The consequence of such opioid regimens is the rapid onset of the adverse side effects including nausea, constipation, respiratory depression, opioid analgesic tolerance and hyperalgesia, and addiction liability, 2 which greatly limits opioid use in patients with neuropathic pain. Preclinical and clinical observations suggest that the reduced analgesic effects of opioids in patients with neuropathic pain may result in part from nerve injury-induced downregulation of opioid receptor mRNA and protein expression in the first-order sensory neurons of the injured dorsal root ganglion (DRG). 11, 14, 29, 32, 40, 51 Therefore, understanding how nerve injury drives opioid receptor downregulation in DRG is essential for improving patient care.
Recent studies showed that the mechanism for gene regulation involves epigenetic modification, such as DNA methylation. 20, 31 DNA methylation represses gene transcription through several mechanisms, such as (1) physically impeding the binding of transcription factors and (2) serving as docking sites for transcription repressors such as the family of methyl-CpGbinding domain (MBD) proteins, including MBD1-4 and MeCP2. 19, 22 DNA methylation is catalyzed primarily by the members of the DNA methyltransferase (DNMT) family, including DNMT1, DNMT3a, and DNMT3b. DNA methyltransferases also contain DNMT2, an inactivated isoform and DNMT3L, which lacks the conserved catalytic domain. 3, 35 Conventionally, DNMT3a and DNMT3b are classified as de novo DNMTs, whereas DNMT1 is considered to be the primary maintenance DNMT. 22 Whether and how DNMTs participate in nerve injuryinduced opioid receptor downregulation in the DRG is elusive.
Here, we showed that the nerve injury-induced increase in DRG DNMT3a is responsible for the MBD1-mediated epigenetic silencing of mu-opioid receptor (MOR) and kappa-opioid receptor (KOR) in the injured DRG under neuropathic pain conditions. DNMT3a seems to be a potential target for improving opioid analgesia in neuropathic pain management.
Materials and methods

Animal preparation
Sprague-Dawley rats were purchased from Charles River Laboratories (Willington, MA). Mbd1 knockout (KO) mice 50 and Dnmt3a fl/fl mice 12 had been bred onto C57B/L6 background for at least 6 generations and were bred by crossing the heterozygotes in our facility. All animals were kept in a controlled 12-hour light-dark cycle, with free access to water and food pellet. Male rats weighing 250 to 300 g and male mice weighing 25 to 30 g were used for behavior testing. All procedures used were approved by the Animal Care and Use Committee at Rutgers New Jersey Medical School and were consistent with the ethical guidelines of the US National Institutes of Health and the International Association for the Study of Pain.
Dorsal root ganglion microinjection
Dorsal root ganglion microinjection was carried out as described. 15, 49 Briefly, a midline skin incision was made in the lower lumbar back region, and the L5 DRG in rats or L4 DRG in mice was exposed. Viral solution (1 mL, 4 3 10 12 ) was injected into the exposed DRG over a period of 10 minutes with a glass micropipette connected to a Hamilton syringe. After each injection, a 10-minute pipette retention was used before the glass pipette was removed. After injection, the surgical field was irrigated with sterile saline and the skin incision was closed with wound clips.
Neuropathic pain models
Spinal nerve ligation (SNL) in rats and mice was performed as previously reported. 15, 33, 45 Briefly, a midline skin incision was made on the lower back. The sixth lumbar transverse process on rats or fifth lumbar transverse process on mice was identified, and then was separated from its muscle attachments. The underlying fifth lumbar spinal nerve in rats or fourth lumbar spinal nerve in mice was isolated and ligated with a 4 to 0 silk suture in rats or 7 to 0 silk suture in mice. The ligated nerve was then transected at the distal end. Sham-operated groups received identical surgical procedures only exposing the nerves without ligation and transection. The surgical field was then irrigated with sterile saline, and the skin incision was closed with wound clips.
Morphine-or loperamide-induced analgesia and tolerance
Analgesia was measured in rats receiving subcutaneous (s.c.) injection of 0.5 mg per kg morphine (WEST-WARD, Eatontown, NJ) or 3 mg per kg loperamide (Sigma, St. Louis, MO). Naltrexone (5 mg per kg; Sigma) or saline was given intraperitoneally 5 minutes before loperamide injection to confirm that loperamide's effect is mediated by MOR. The thermal test as described below was performed before and 20 minutes after s.c. morphine or loperamide injection. Analgesic tolerance was induced in rats as previously described. 17, 46 Briefly, morphine (10 mg per kg) was injected s.c. twice daily for 6 consecutive days in naive rats or twice daily for 4 consecutive days starting on day 7 after SNL. Loperamide (10 mg per kg, s.c. in naive rats, and 0.75 mg per kg in SNL rats) was injected twice daily for 5 consecutive days in naive rats or twice daily for 3 consecutive days starting on day 7 post-SNL. For morphine tolerance, the thermal test was performed before morphine injection and 20 minutes after s.c. injection of an inducing dose of morphine (5 mg per kg in naive rats and 1.5 mg per kg in SNL rats) on the mornings of days 1, 3, 5, and 7 in naive rats or on the mornings of days 7, 9, and 11 post-SNL. For loperamide tolerance, the thermal test was performed before and 20 minutes after the s.c. injection of loperamide on the mornings of days 1, 3 and 5 in naive rats and days 7, 8, and 9 post-SNL. Cumulative morphine dose-response test was performed as described previously 18, 46 on the afternoon of day 7 in naive rats or on the afternoon of day 11 post-SNL. Rats were injected s.c. with a low dose of morphine (1 mg per kg), and analgesia was assessed 20 minutes later by the thermal test. Rats that were not analgesic at the first dose then received a second dose (cumulative dosing increase by 0.3 log units) and were tested 20 minutes afterward. This procedure was repeated until the rats failed to move their tail within the cut-off time or no additional increase in paw withdrawal latency was noted from one dose to the next.
Thermal behavioral tests
Thermal test was performed as previously described. 15, 46, 49 Briefly, each rat was placed in a plexiglas chamber on an elevated grid and acclimated for 30 minutes before behavioral test. Paw withdrawal latencies to noxious heat were measured with a Model 336 Analgesic Meter (Life Science Instruments, Woodland Hills, CA). A beam of light giving radiant heat was aimed to the middle of the plantar surface of each hind paw through the glass plate. When the animal withdrew its paw, the light beam was turned off. The length of time between the onset of the light beam and paw withdrawal was defined as the paw withdrawal latency. Each trial was repeated 3 times at 5-minute intervals for each side. A cut-off time of 20 seconds was used to avoid tissue damage. Paw withdrawal latencies were converted to the percentage of the maximal possible antinociceptive effect (% maximal possible analgesic effect [MPAE]): % MPAE 5 ([response latency 2 baseline latency]/[cut-off latency 2 baseline latency]) 3 100%.
Reverse transcription PCR
Two rat DRG or 4 mouse DRG were pooled together to achieve enough RNA. Total RNA was prepared using miRNeasy Mini Kit (Qiagen, Valencia, CA), following the manufacturer's instruction. Briefly, the pooled DRG were homogenized with 700-mL lysis reagent, extracted by 140-mL chloroform, and centrifuged for 15 minutes at 312,000g at 4˚C. RNA was then precipitated with 100% ethanol, treated with DNase I, and eluted with 35-mL RNase-free water. After concentration measurement, the RNA was first reverse transcribed to cDNA using the ThermoScript reverse transcriptase (ThermoFisher Scientific, Grand Island, NY) and oligo (dT) primers (ThermoFisher Scientific). Template (1 mL) was amplified by real-time PCR using the primers listed in Table 1 . Gapdh was used as an internal control for normalization. Each sample was run in triplicate in a 20-mL reaction with 250 nM forward and reverse primers, 10 mL of SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA), 
ChIP, chromatin immunoprecipitation; Dnmt, DNA methyltransferase; F, forward; Mbd, methyl-CpG-binding domain; R, reverse; underlined letters, the restriction enzyme recognition sites.
June 2017 · Volume 158 · Number 6 www.painjournalonline.com and 20 ng of cDNA. Reactions were performed in a BIO-RAD CFX96 real-time PCR system. Ratios of ipsilateral-side mRNA levels to contralateral-side mRNA levels were calculated using the DCt method (2 2DDCt ). All data were normalized to Gapdh, which has been demonstrated to be stable even after peripheral nerve injury insult. 15, 49 2.7. Plasmid constructs and virus production A Dnmt3a shRNA duplex corresponding to bases 2576 to 2594 from the open reading frame of rat Dnmt3a mRNA (GenBank accession number NM_001003958) was designed. A mismatch shRNA with a scrambled sequence and no known homology to a rat gene (scrambled shRNA) was used as a control. shRNAs were synthesized and were amplified using AAV-shRNA-Ctrl-EYFP and the primers listed in Table 1 . Fragments harboring Dnmt3a shRNA and Dnmt3a scrambled shRNA were ligated into pro-viral plasmids using AgeI and XbaI restriction sites. The resulting vectors expressed the genes under the control of the cytomegalovirus promoter. Rat full-length Dnmt3a cDNA was purchased from OriGene (Rockville, MD). Mouse full-length Mbd1 cDNA was amplified from total RNA of mouse DRG using the same kit as described above and the primers listed in Table 1 . Adenoassociated virus type 5 (AAV5) particles carrying the cDNA were produced at the UNC Vector Core (Chapel Hill, NC). AAV5-green fluorescent protein (GFP) and AAV5-Cre were purchased from the UNC Vector Core. Herpes simplex virus (HSV)-GFP and HSVDnmt3a were provided by E.J.N.
Dorsal root ganglion cell culture and viral transfection
Adult wild type (WT) mice, Dnmt3a fl/fl mice, or Mbd1 KO mice were euthanized with isoflurane and all DRG were collected in cold Neurobasal Medium (ThermoFisher Scientific) with 10% fetal bovine serum (JR Scientific, Woodland, CA), 100 units per mL penicillin, and 100 ug per mL streptomycin (Quality Biological, Gaithersburg, MD). Collected DRG were cut into smaller pieces and then treated with enzyme solution (5 mg per mL dispase, 1 mg per mL collagenase type I in Hanks balanced salt solution without Ca 21 and Mg 21 [ThermoFisher Scientific]). After trituration and centrifugation, dissociated cells were resuspended in mixed Neurobasal Medium and plated in a 6-well plate precoated with 50 ug per mL poly-D-lysine (Sigma). The cultured neurons were incubated at 95% O 2 , 5% CO 2 , and 37˚C. After 24 hours, 1 to 10 mL of virus (titer: 1 3 10 12 per mL) was added to each 2 mL well. The cells were harvested 3 days later for reverse transcription PCR.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were conducted using the EZ ChIP Kit (EMD Millipore, Darmstadt, Germany), following the manufacturer's instruction with minor modifications. Two DRG from rats or 5 DRG from mice were harvested and homogenized. The homogenization solution was then crosslinked with 1% formaldehyde for 10 minutes at room temperature. The reaction was quenched by adding 0.125 M glycine solution for 5 minutes at room temperature. After centrifugation, the collected pellet was lysed in sodium dodecyl sulfate lysis buffer containing protease inhibitor cocktail (Upstate Biotechnology) and sonicated to yield fragments with a length of 200;1000 bp. After the samples were precleared with protein G agarose beads for 1 hour at 4˚C with agitation, they were subjected to immunoprecipitation overnight with 2 mg of rabbit antibodies against DNMT3a (Abcam, Cambridge, MA) or MBD1 (Abcam) or with 2 mg of normal rabbit serum overnight at 4˚C. Input (10%-20% of the sample for immunoprecipitation) was used as a positive control. The DNA fragments were purified and identified using PCR or real-time PCR with the primers listed in the Table 1 .
Bisulfite sequencing
L5 DRG were harvested 7 days after SNL or sham surgery. Two DRG were pooled together for DNA extraction. Bisulfite treatment of genomic DNA was performed using the EZ DNA MethylationGold Kit (ZYMO Research, Irvine, CA) according to the manufacturer's instructions. The region of the Oprm1 gene promoter from 2670 to 1450 bp consisted of 38 CpG sites was amplified. For the pyrosequencing assay, 3 pairs of primers of the Oprm1 gene with 59-biotin listed in the Table 1 were used to amplify the bisulfite DNA. The master mix of the binding buffer, streptavidin-sepharose beads, and PCR products were prepared for the binding reaction in a 96-well plate. After sealing the plate with sticker film, the plate was placed on the shaker for at least 15 minutes, but no longer than 1 hour. The pyrosequencing was then performed. For the clone-sequencing assay, the same promoter fragment was amplified. The PCR products were purified and subcloned into pMD T-19 vector (Clontech Laboratories, Mountain View, CA) and transformed into competent cells. After overnight bacterial culture, 20 subclones from each assay were subjected to PCR amplification and direct sequencing. The primers we used are listed in the Table 1 .
Immunohistochemistry
Rats were anesthetized with isoflurane and perfused with 300 mL of 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) (pH 7.4). After perfusion, L4 and L5 DRGs were dissected, postfixed at 4˚C for 4 hours and cryoprotected in 30% sucrose overnight. The transverse sections were cut on a cryostat at a thickness of 25 mm. Three sets of the sections were collected. The sections were blocked for 1 hour at 25˚C in 0.01M PBS containing 10% goat serum and 0.3% Triton X-100. One set of sections was incubated overnight at 4˚C with rabbit anti-DNMT3a (1:500; Santa Cruz Biotechnology, Inc., Dallas, TX) plus guinea pig anti-MOR (1:1,000; EMD Millipore, Darmstadt, Germany) and the second with rabbit antiDNMT3a plus mouse anti-KOR (1: 200; Neuromics, Edina, MN). The sections were then incubated with a mixture of goat anti-rabbit antibody conjugated to Cy3 (1:200; Jackson ImmunoResearch, West Grove, PA) and donkey anti-guinea pig antibody conjugated to Cy2 (1:200; Jackson ImmunoResearch) or with a mixture of goat anti-rabbit conjugated to Cy3 and donkey anti-mouse antibody conjugated to Cy2 (1: 200; Jackson ImmunoResearch) for 2 hours at room temperature. The third set of sections was used for control experiments, which included preabsorption of the primary antibodies with excess of the corresponding antigens, substitution of the normal serum, and omission of the primary antibodies. Immunofluorescence-labeled images were generated using a Leica DMI4000 fluorescence microscope with a DFC365FX camera (Leica, Germany).
Western blotting
Two unilateral rat DRG or 4 unilateral mouse DRG were pooled together to obtain enough proteins. Tissues were prepared as previously described. 15, 49 Briefly, DRG were homogenized with ice-cold lysis buffer (10 mM Tris, 5 mM EGTA, 0.5% Triton X-100, 2 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, 40 mM leupeptin, and 150 mM NaCl). The crude homogenate was centrifuged at 4˚C for 15 minutes at 1000g. The supernatants were collected for cytoplasmic protein detection. The pellets were further sonicated and dissolved in nucleus-soluble ice-cold buffer (1M Tris-HCl, 1% SDS, and 0.1% Triton X-100). After protein concentration was measured, the samples were heated at 99˚C for 5 minutes and loaded onto a 4% to 15% stacking and 7.5% separating Sodium dodecyl sulfatepolyacrylamide gel (Bio-Rad, Hercules, CA). The proteins were then electrophoretically transferred onto a polyvinylidene difluoride membrane (Bio-Rad). The membrane was blocked with 3% nonfat milk in Tris-buffered saline (pH 7.40) containing 0.1% Tween-20 for 1 hour and then incubated with primary antibodies overnight under gentle agitation. The primary antibodies used include rabbit anti-DNMT3a (1:500, Cell Signaling Technology, Danvers, MA), rabbit anti-DNMT3b (1:500, Santa Cruz Biotechnology), rabbit anti-DNMT1 (1:500, Cell Signaling Technology), rabbit anti-mTOR (1:1000, Cell Signaling Technology), rabbit anti-MOR (1:500, Neuromics), rabbit anti-KOR (1:500, NOVUS Biologicals, Littleton, CO), mouse anti-MBD1 (1:200, provided by Dr. Xinyu Zhao), rabbit anti-mTOR (1:2,000, Cell Signaling Technology), rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:1000, Santa Cruz Biotechnology), mouse anti-tubulin (1:1,000, Santa Cruz Biotechnology), or rabbit anti-histone H3 (1:1,000, Cell Signaling Technology). The proteins were detected by horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:3,000; Jackson ImmunoResearch) and visualized by chemiluminescence regents (ECL, Bio-Rad). Images were generated using the ChemiDoc XRS System with Image Lab software (Bio-Rad).
Intensities of protein bands were quantified using Image Lab software. All cytosol protein bands were normalized to either GAPDH or tubulin, whereas nucleus protein bands were normalized to total histone H3.
Whole-cell patch clamp recording
Adult rat spinal cord slices were prepared as described. 38 Briefly, rats (age . 21 days) were deeply anesthetized with isoflurane. Laminectomy was applied from midthoracic to lower lumbar levels. The spinal cord was quickly removed and placed in coldmodified artificial cerebrospinal fluid containing: (in mM) 80 NaCl, 2. Whole-cell patch recording was performed as described. 38 The slice was transferred to a recording chamber (Warner Instruments, Hamden, CT) and perfused with oxygenated recording solution at a rate of 3 mL per minute at room temperature. Neurons were identified by infrared differential interference contrast with an upright microscope DM6000 To record mEPSC, 500 nM tetrodotoxin was presented at the recording solution. To record eEPSC, a suction electrode (A-M systems) was used for electrical stimulation of the attached dorsal root. Stimulation was delivered by the suction electrode with a constant current stimulator S88 (Grass, Rockland, MA). To verify different primary afferent inputs, Ab fiber-eEPSCs were classified as monosynaptic by constant latency and absence of failures on 25 uA with 20 Hz stimulation; Ad fiber-eEPSCs were classified as monosynaptic by constant latency and absence of failures on 100 uA with 2 Hz stimulation; C fiber-eEPSCs were classified as monosynaptic by absence of failures on 500 uA with 1 Hz stimulation. The conduction velocity was further measured to distinguish the primary afferent input (C , 0.8 m/s). 23, 39 Only C fiber input monosynaptic neurons were measured for further experiments. Measurements were made from only 1 neuron per slice. The pair pulse protocol was delivered by S88 with 20 Hz frequency and 50 ms pulse interval. The signals were filtered at 2 kHz. Data were stored on a computer using the DigiData 1550 interface and were analyzed by the pCLAMP 10.4 software package (Molecular Devices). All experiments were performed at room temperature.
Statistical analysis
All the results are given as mean 6 SEM. The data were statistically analyzed with 2-tailed, paired Student t test and a 1-way or 2-way analysis of variance. When analysis of variance showed a significant difference, pairwise comparisons between mean values were tested by the post hoc Tukey method (SigmaPlot 12.5; San Jose, CA). Significance was set at P , 0.05. 
Results
DNMT3a regulation of mu-opioid receptor and kappaopioid receptor expression in the dorsal root ganglia of naive or spinal nerve ligation rats
Our recent study demonstrated a significant increase in the level of DNMT3a protein in the injured DRG neurons after peripheral nerve injury. 48 Given that DNMT3a is a repressor of gene expression, 20, 48 we first asked whether this increased DNMT3a participated in nerve injury-induced downregulation of DRG opioid receptors. shRNA strategy was performed to knockdown DRG DNMT3a expression through unilateral DRG microinjection of AAV5 that expresses Dnmt3a shRNA. 48 AAV5 that expresses scrambled shRNA was used as a control. Because AAV5 transduces the neurons, but not the satellite cells, after viral microinjection into the DRG, 49 the delivered Dnmt3a shRNA expresses predominantly in the DRG neurons, in which DNMT3a is exclusively distributed. 48 Specific and selective effects of Dnmt3a shRNA were verified by its ability to knockdown DNMT3a, but not DNMT1, DNMT3b, or an intracellular protein mTOR in the injected DRG of naive rats 5 weeks after viral microinjection ( Fig. 1A; Supplementary Fig. 1 , available online at http://links.lww.com/PAIN/A399). The basal levels of MOR and KOR proteins in the injected DRG from the AAV5-Dnmt3a shRNA-injected group were higher than those from either the PBS-or AAV5-scrambled shRNA-treated group (Fig. 1A) . Consistent with the previous studies, 14 ,29 the amounts of MOR and KOR proteins (Fig. 1B) and Oprm1, Oprd1, and Oprk1 mRNAs (Fig. 1C) were significantly reduced in the ipsilateral L5 (injured) DRG on day 7 postunilateral L5 SNL in the AAV5-scrambled shRNA plus SNL group. The reductions in the levels of Oprm1 and Oprk1 mRNAs and their coding proteins (but not Oprd1 mRNA) in the injured DRG were abolished in the AAV5-Dnmt3a shRNA plus SNL group (Fig. 1B, C) . As expected, basal levels of Oprm1 and Oprk1 mRNAs in the ipsilateral L5 DRG from the AAV5-Dnmt3a shRNA plus sham group increased (Fig. 1C) .
Given that shRNA may have off-target effects, we further confirmed DNMT3a regulation of opioid receptors in neuropathic pain using microinjection of AAV5-Cre into the ipsilateral L4 DRG of Dnmt3a fl/fl mice 5 weeks before unilateral L4 SNL or sham surgery.
33 AAV5-GFP was used as a control. Injection of AAV5-Cre, but not AAV5-GFP, prevented SNL-induced upregulation of Dnmt3a mRNA and its coding protein and reversed downregulation of Oprm1 and Oprk1 mRNAs and their coding proteins (but not Oprd1 mRNA) in the ipsilateral L4 DRG of Dnmt3a fl/fl mice on day 7 post-SNL (Supplementary Fig. 2A and 2B, available online at http://links.lww.com/PAIN/ A399). As expected, in the ipsilateral L4 DRG of sham Dnmt3a fl/fl mice, AAV5-Cre injection markedly decreased the basal level of Dnmt3a mRNA and increased basal amounts of Oprm1 and Oprk1 mRNAs on day 7 after sham surgery (Supplementary Fig. 2A and 2B, available online at http://links. lww.com/PAIN/A399).
We further tested whether mimicking the nerve injuryinduced increase in DRG DNMT3a through microinjection of AAV5-Dnmt3a (that expresses full-length DNMT3a) into the unilateral L4 and L5 DRGs affected DRG opioid receptor expression. As shown in Figure 1D , E, the levels of Dnmt3a mRNA and its coding protein in the AAV5-Dnmt3a-treated group markedly increased, compared with the control AAV5-GFP group, in the injected DRG 5 weeks postinjection. The levels of Oprm1 and Oprk1 mRNAs and their coding proteins, but not Oprd1 mRNA, in the injected DRG from the AAV5-Dnmt3a-injected group significantly decreased compared with those from the PBS-or AAV5-GFP-injected group (Fig.  1F) . The evidence suggests that DNMT3a directly regulates Oprm1 and Oprk1 gene expression. Indeed, immunohistochemical double-labelling staining showed that approximately 83.7% of MOR-labeled DRG neurons and 75.5% of KORlabeled DRG neurons were positive for DNMT3a (Fig. 1G) . Knockdown of DNMT3a through transduction of AAV5-Cre in in vitro cultured DRG neurons of Dnmt3a fl/fl mice substantially increased Oprm1 and Oprk1 mRNA expression (Supplementary Fig. 3 , available online at http://links.lww.com/PAIN/ A399). These increases could be prevented by cotransduction of AAV5-Cre and HSV-Dnmt3a ( Supplementary Fig. 3 , available online at http://links.lww.com/PAIN/A399). As expected, HSV-Dnmt3a transduction alone reduced the levels of Oprm1 and Oprk1 mRNAs ( Supplementary Fig. 3 , available online at http://links.lww.com/PAIN/A399). Oprd1 mRNA expression was not altered in the cultured DRG neurons transduced by single virus or their combinations ( Supplementary Fig. 3 , available online at http://links.lww. com/PAIN/A399). The evidence described above strongly suggests the contribution of DNMT3a to nerve injury-induced downregulation of MOR and KOR, but not DOR, in the injured DRG. www.painjournalonline.com 1159
Effect of dorsal root ganglion DNMT3a knockdown on morphine/loperamide analgesia and their tolerance in naive or spinal nerve ligation rats
Next, we examined the role of DRG DNMT3a in opioid analgesia. Given that morphine binding predominantly to MOR is often used in pain management, we observed whether DNMT3a knockdown in DRG altered morphine analgesia and morphineinduced tolerance in naive animals. As indicated in Figure 2A , the AAV5-Dnmt3a shRNA-treated rats, but not the PBS-or AAV5-scrambled shRNA-treated rats, displayed a significant increase in morphine's MPAE on the ipsilateral (not contralateral) side after s.c. administration of a single low dose of morphine (0.5 mg per kg). Consistent with previous studies, 46 repeated s.c. injection of morphine (10 mg per kg, twice daily) in naive rats produced morphine analgesic tolerance as indicated by time-dependent decreases in morphine MPAEs in the PBSinjected group (Fig. 2B, C) . These decreases were markedly attenuated on days 5 and 7 after morphine injection on the ipsilateral (but not contralateral) side of the AAV5-Dnmt3a shRNA-treated, but not AAV5-scrambled shRNA-treated, groups (Fig. 2B, C) . This effect of AAV5-Dnmt3a shRNA was further verified by a significant leftward shift in the cumulative dose-response curve of morphine in the AAV5-Dnmt3a shRNAtreated group compared with the PBS-or AAV5-scrambled shRNA-treated group on the last day after repeated s.c. administration of morphine (Fig. 2D) . The EC 50 values of morphine in the AAV5-Dnmt3a shRNA-treated group (5.65 mg per kg) was substantially smaller than those in the PBS-treated (10.36 mg per kg) and AAV5-scrambled shRNA-treated (10.59 mg per kg) groups (Fig. 2D) . Furthermore, we examined whether DNMT3a knockdown in the injured DRG improved morphine analgesia and alleviated morphine-induced tolerance under neuropathic pain conditions. As expected, when the first dose of morphine was administered s.c. on day 7 after SNL, morphine MPAE was much greater in the AAV5-Dnmt3a shRNA-treated group than that in the PBS-or AAV5-scrambled shRNA-treated group on the ipsilateral side (Fig. 2E) . Repeated s.c. morphine administration twice daily for 5 days starting from day 7 after SNL also led to a time-dependent reduction in morphine MPAE in the PBS-or AAV5-scrambled shRNA-treated groups (Fig. 2E) . However, this reduction was significantly prohibited in the AAV5-Dnmt3a shRNA-treated group (Fig. 2E) . This effect of AAV5-Dnmt3a shRNA was also confirmed by a significant leftward shift in the cumulative dose-response curve of morphine in the AAV5-Dnmt3a shRNA-treated group compared with the PBS-or AAV5-scrambled shRNA-treated group on the last day after repeated s.c. administration of morphine (Fig. 2F) . The EC 50 values of morphine were 3.50 mg per kg in the AAV5-Dnmt3a shRNA-treated group, 7.02 mg per kg in the PBStreated group, and 7.32 mg per kg in the AAV5-scrambled shRNA-treated group (Fig. 2F) . It is evident that blocking increased DNMT3a, improves morphine analgesia, and prevents morphine analgesic tolerance development under neuropathic pain conditions. Analgesic effects caused by s.c. injection of morphine are mediated by MOR located in both peripheral and central nervous systems. To further demonstrate the role of DRG DNMT3a in peripheral MOR-mediated analgesia in naive and SNL animals, we subcutaneously injected loperamide, which is a peripheral acting MOR preferring agonist that does not penetrate the blood-brain barrier. 7 Like morphine, loperamide produced similar behavioral responses seen in naive and SNL rats from the PBSand virus-treated groups (Fig. 3A-D) .
Effect of increased DNMT3a in the dorsal root ganglion on mu-opioid receptor-gated primary afferent neurotransmitter release
Mu-opioid receptor expressed in small primary afferents controls neurotransmitter release from their central terminals. 8, 37 Mu-opioid receptor downregulation in the injured DRG augments the release of primary afferent neurotransmitters in neuropathic pain. 34, 36 We further tested whether mimicking the nerve injury-induced increase in DRG DNMT3a Figure 4 . Overexpression of DNMT3a in DRG promotes neurotransmitter release from primary afferents. All the following experiments were performed 5 weeks after microinjection of AAV5-Dnmt3a (DNMT3a), or AAV5-GFP (control) into unilateral L4 and L5 DRGs. (A) Example traces of miniature EPSC (mEPSC) recorded in lamina II dorsal horn neurons before and after DAMGO application and its wash out. (B and C) Effects of DAMGO (1 mM) on the frequency (B) and amplitude (C) of mEPSC in lamina II neurons from the AAV5-Dnmt3a-treated group (n 5 19 neurons, 9 rats) and control group (n 5 26 neurons, 12 rats). *P , 0.05, **P , 0.01 vs the control group before DAMGO application. (D) Example traces of C-fiber input-evoked EPSC in lamina II neurons before and after DAMGO application and its wash out. (E and F) Effects of DAMGO (1 mM) on the paired pulse ratio (E) and first peak amplitude of EPSC (F) in lamina II neurons from the AAV5-Dnmt3a-treated group (n 5 16 neurons, 19 rats) and control group (n 5 23 neurons, 20 rats). *P , 0.05, **P , 0.01 vs the control group before DAMGO application. DNMT, DNA methyltransferase; DRG, dorsal root ganglion; EPSC, excitatory postsynaptic current. through microinjection of AAV5-Dnmt3a into the unilateral L4 and L5 DRGs affected primary afferent neurotransmitter release. To this end, we first measured the changes in mEPSC frequencies, which reflected the alteration in presynaptic neurotransmitter release, 44, 47 recorded in lamina II neurons from L4 and L5 spinal cord slices 5 weeks postviral injection. Miniature EPSC frequency in the AAV5-Dnmt3a-treated group was significantly higher than that in the control AAV5-GFP-treated group (Fig. 4A, B) . To verify whether this alteration was attributed to the reduction of MOR function in primary afferents, we applied the selective MOR agonist DAMGO. DAMGO (1 mM) led to a greater decrease in mEPSC frequency in the control group (46.93 6 4.38%) than that in the AAV5-Dnmt3a-treated group (26.23 6 3.79%) (Fig. 3D) . This effect was abolished after DAMGO wash out (Fig. 4B) or by the addition, before DAMGO treatment, of the selective MOR antagonist CTOP (data not shown). Miniature EPSC amplitude was not altered in the 2 groups with or without DAMGO application (Fig. 4C) . The evidence suggests that increased DNMT3a expression in DRG results in an increase in MORgated presynaptic neurotransmitter release.
The mEPSCs recorded above may reflect overall excitatory inputs from both primary afferents and interneurons to the recorded neurons. 44, 47 To further examine the role of DNMT3a in the release of primary afferent neurotransmitters, we recorded the EPSCs evoked by stimulation of the dorsal root (C-fiber: 500 mA intensity and 1 Hz) with a paired-pulse protocol. The paired-pulse ratio (PPR), which reflects the probability of primary afferent neurotransmitter release, 44, 47 was determined by dividing the second peak amplitude by the first one. The PPR significantly declined in the AAV5-Dnmt3a-treated group compared with the control group (Fig. 4D, E) . In addition, the first peak amplitude of the EPSC in the AAV5-Dnmt3a-treated group was higher than that in the control group (Fig. 4D, F) . DAMGO application markedly increased the PPR by 15.85% and decreased the first peak amplitude by 29.56% in the control group, but only 8.85% and 17.78%, respectively, in the AAV5-Dnmt3a-treated group (Fig. 4D, F) . DAMGO effects could be abolished after its wash out (Fig. 4F) or by previous treatment with CTOP (data not shown). These results suggest that increased DNMT3a in DRG promotes neurotransmitter release from primary afferent terminals possibly through presynaptic MOR downregulation in DRG. We further examined whether SNL altered the DNA methylation level of the Oprm1 gene and whether DNMT3a was involved in this alternation in the injured DRG. We first used chromatin immunoprecipitation assays and identified that DNMT3a bonds to 3 regions (2450 to 2288 bp, 1142 to 1 312 bp, and 1238 to 1439 bp) of the Oprm1 gene as demonstrated by the amplification of only these 3 regions (of the 7 regions from 2450 to 1558 bp) from the complexes immunoprecipitated with DNMT3a antibody in nuclear fractions from sham DRG (Fig. 5A) . The binding activities in these 3 regions in the injured DRG on day 7 after SNL increased by 1.8-fold, 1.5-fold, and 2-fold, respectively, compared with those after sham surgery (Fig. 5B) . Furthermore, these increased binding activities affected the DNA methylation pattern and level in the promoter and 59end untranslated regions of the Oprm1 gene after SNL. The bisulfite clone-sequencing assay showed increases in DNA methylation levels at -365 and 1387 CpG sites (Fig. 5C ), which are located within the DNMT3a-binding regions described above. The bisulfite pyrosequencing assay further confirmed the increases in DNA methylation in these 2 CpG sites, although the increases in DNA methylation were detected at additional 2132 and 1438 CpG sites (Fig.  5D ). More importantly, this increase in DNA methylation may be dependent on DNMT3a expression, as DRG DNMT3a knockdown abolished the SNL-induced increase in the methylation at the 2365 CpG site (Fig. 5E ).
MBD1 participates in DNMT3a regulation of mu-opioid receptor expression in dorsal root ganglion neurons
DNA methylation-gated gene expression also requires the participation of the family of MBD proteins including MBD1-3 and MeCP2. 19, 22 Except for MBD3, the remaining proteins function as methylation-dependent transcriptional repressors. [24] [25] [26] Here, we demonstrated that MBD1 bonds to 3 regions (2450 to 2288 bp, 2310 to 2143 bp, and 2164 to 26 bp) (of the 7 regions from 2450 to 1558 bp) of the Oprm1 gene in sham DRG (Fig. 5A ). MBD1 and DNMT3a have an overlapping binding region (2450 to 2288) within the Oprm1 gene. Moreover, MBD1-binding activity at this overlapping region in the injured DRG on day 7 after SNL increased by 1.64-fold compared with that after sham surgery (Fig. 6A) . This suggests that MBD1 is involved in DNMT3a regulation of Oprm1 gene expression in DRG neurons. To address this conclusion, we used MBD1 KO mice ( Supplementary Fig. 4 , available online at http://links.lww.com/PAIN/A399) and revealed the requirement of MBD1 for DNMT3a binding to the Oprm1 gene in DRG as demonstrated by almost failure to the amplification of the Oprm1 gene from the complexes immunoprecipitated with DNMT3a antibody in nuclear fractions from MBD1 KO DRG, compared with that from the WT DRG (Fig. 6B) . We then overexpressed DNMT3a in the DRG neurons by transducing HSV-Dnmt3a into the cultured DRG neurons from the WT and KO mice (Fig. 6C) . HSV-GFP was used as a control. As expected, the level of Oprm1 mRNA in the HSV-Dnmt3a-treated group significantly decreased compared with the AAV5-GFP-treated group from the WT mice (Fig. 6C) . In contrast, the amount of Oprm1 mRNA was highly elevated in both viral treatment groups from the KO mice (Fig. 6C) . Finally, we coexpressed DNMT3a and MBD1 in the DRG neurons by cotransduction of HSV-Dnmt3a and AAV5-Mbd1 (that expresses full-length MBD1) into the cultured DRG neurons from the WT mice (Fig. 6D, E) . This cotransduction markedly reduced the Oprm1 mRNA expression although single transduction of each gene did not alter the level of the Oprm1 mRNA (Fig. 6F) . These in vitro findings strongly support the involvement of MBD1 in DNMT3a regulation of the Oprm1 gene.
Discussion
This study demonstrated that nerve injury-induced increase in DRG DNMT3a is responsible for epigenetic silencing of DRG Oprm1 and Oprk1 genes and opioid analgesic reduction under neuropathic pain conditions. Mechanistically, the increased DNMT3a repressed MOR expression by promoting the MBD1-mediated DNA methylation in the promoter and 59-untranslated region of the Oprm1 gene. These findings suggest that inhibition of DRG DNMT3a may improve opioid analgesic effects in treating neuropathic pain.
The Dnmt3a gene could be transcriptionally activated in the injured DRG neurons after peripheral nerve injury. The amounts of Dnmt3a mRNA and its coding DNMT3a protein significantly and time-dependently increased through the activation of the transcription factor octamer transcription factor 1 in the injured DRG after SNL or chronic construction injury (CCI). 48 Given that DNMT3a is a gene repressor 20, 31 and expressed exclusively in DRG neurons, 48 the increased DNMT3a likely participates in nerve injury-induced downregulation in gene expression in the injured DRG neurons. It should be pointed out that DNMT3a has 2 isoforms, the long DNMT3a1 and the shorter DNMT3a2, which differ in that a 219-amino-acid Nterminal tail is present only in DNMT3a1. 4, 43 The DNMT3a antibody used in this study was generated against DNMT3a amino acids 15 to 126 and thus actually detected the expressional increase of DNMT3a1 isoform, although our quantitative reverse transcription PCR assay displayed the expressional elevations of both DNMT3a1 and DNMT3a2 mRNAs in the injured DRG. Whether peripheral nerve injury alters DRG DNMT3a2 isoform expression remains to be determined after the primary antibody specifically and selectively against DNMT3a2 is available commercially.
We demonstrated that DNMT3a is essential for epigenetic silencing of Oprm1 and Oprk1 genes in the injured DRG under neuropathic pain conditions. A previous study showed that CCI-induced MOR downregulation might be attributed to increases in the levels of DNA methylation within the Oprm1 gene at 2388, 2344, and 2255 CpG sites in the injured mouse DRG, 51 because blocking these increases through intrathecal 5-aza-dC (a nonspecific DNMT inhibitor) rescued the expression of Oprm1 mRNA and its coding protein in the injured DRG and restored morphine analgesic effects after CCI. 51 However, how nerve injury causes an increase in Oprm1 gene methylation is unknown. Moreover, which members of the DNMT family are responsible for this increase are unclear.
This study demonstrated that DNMT3a bound to 3 regions (2450 to 2288, 1142 to 1312, and 1238 to 1439) within the Oprm1 gene in rat DRG. The binding activities in these 3 regions were increased in the injured DRG after SNL. Furthermore, the DNMT3a-triggered increases in DNA methylation were identified at 2365 and 1387 CpG sites within the Oprm1 gene in the injured rat DRG. These 2 methylated sites were different from the ones reported previously. 51 The reasons in the difference between this study and previous studies are unknown, but may be related to the use of distinct neuropathic pain models (SNL vs CCI) and animal species (rats vs mice). In addition to Oprm1 mRNA, DNMT3a is involved in nerve injury-induced downregulation of Oprk1 mRNA and its coding KOR, but not Oprd1 mRNA, in the injured DRG. How DNMT3a specifically and selectively targets Oprm1 and Oprk1 genes is still elusive, but DNMT3a participation in nerve injury-induced DRG Oprm1 silencing may require MBD1. MBD1 as a transcriptional repressor binds more efficiently to methylated DNA with a specific sequence context. 5 Selective and specific targeting of DNMT3a on the Oprm1 and Oprk1 genes is likely associated with the characteristics of MBD1 sequence-specific binding to the genes. It is worth noting that DNMT3a may participate in nerve injury-induced silencing of other genes (such as Kcna2) in the injured DRG. 48 The mechanisms by which nerve injury causes a reduction in systemic, spinal, and peripheral opioid analgesia are complicated and may involve DRG opioid receptor downregulation, descending spinal facilitation, enhanced excitatory neurotransmitter release in primary afferents, glutamate receptor and glial cell activation, and cytokine release in spinal cord and brain regions under neuropathic pain conditions. 6, 10, 13, [28] [29] [30] 32, 40, 42, 51 The data from this study demonstrated that rescuing MOR downregulation by blocking increased DNMT3a in the injured DRG, significantly restored analgesia to systemically administered morphine or loperamide, and attenuated the development of their analgesic tolerance after SNL. This suggests that the nerve injury-induced reduction in opioid analgesia could be due at least in part to DNMT3a-triggered DRG MOR silencing. The previous studies revealed that other epigenetic modifications might also regulate MOR-gated analgesic actions under neuropathic pain conditions. Peripheral nerve injury increased the enrichment of the G9a-catalyzed histone 3 at lysine 9 dimethylation in the promoter of the Oprm1 gene and decreased neuron-restrictive silencer factor-mediated histone 3 and 4 acetylation within the Oprm1 gene, both of which result in DRG Oprm1 gene silencing and morphine analgesic reduction. 16, 40, 51 It is evident that nerve injury-induced downregulation of DRG MOR and the reduction of morphine analgesia may be controlled by multiple epigenetic mechanisms.
DNMT3a-triggered silencing of the Oprm1 gene in the injured DRG is implicated in the mechanism of neuropathic pain development. Mu-opioid receptor downregulation in the injured DRG augments the release of primary afferent neurotransmitters after peripheral nerve injury. 34, 36 Mu-opioid receptor knockout mice displayed increased mechanical pain hypersensitivity under neuropathic pain conditions. 21 These findings imply that nerve injury-induced MOR downregulation in the injured DRG might participate in the mechanism of neuropathic pain through a loss of tonic MOR-mediated inhibition at central terminals of the primary afferents. This study showed that the increased DRG DNMT3a augmented MOR-gated neurotransmitter release from the primary afferents. Our recent work demonstrated that blocking increased DNMT3a in the injured DRG and attenuated the development of nerve injury-induced pain hypersensitivity.
The evidence suggests that DRG DNMT3a participates in neuropathic pain development at least in part through the mechanism of its triggered DRG MOR downregulation.
In summary, we demonstrated a DNMT3a-triggered epigenetic mechanism of how MOR is downregulated in the injured DRG under neuropathic pain conditions. We also reported that blocking increased DRG DNMT3a rescues morphine analgesia and prevents morphine-induced analgesic tolerance after peripheral nerve injury. DNMT3a is likely a novel target for adjunctive use with opioids in treating neuropathic pain.
